72-69-5 Usage
Originator
Aventyl,Lilly,UK,1963
Uses
Different sources of media describe the Uses of 72-69-5 differently. You can refer to the following data:
1. Nortriptyline is a drug with a relatively short latent period of action. It is
practically devoid of sedative effects. It is used in manic-depressive psychoses, in all forms
of endogenous depression, and also in major depressive conditions.
2. Antidepressant.
Definition
ChEBI: An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Manufacturing Process
A mixture of 114.5 g of 5-(3-chloropropylidene)dibenzo[a,d]cyclohepta[1,4] diene, 75 ml of benzene, and about 400 ml of methylamine is heated in an autoclave at 120°C for six hours. The excess methylamine is distilled from the reaction mixture under vacuum and the residue is stirred with 300 ml of water. Acidification of the mixture with hydrochloric acid causes the separation of the hydrochloride of 5-(3-methylaminopropylidene)dibenzo[a,d]
cyclohepta[1,4]diene. The product is collected by filtration and is purified by recrystallization from a mixture of absolute ethanol and ethyl acetate. MP 210°C to 212°C.
Brand name
Aventyl Hydrochloride (Lilly); Aventyl Hydrochloride (Ranbaxy); Pamelor (Tyco).
Therapeutic Function
Antidepressant
Clinical Use
Tricyclic antidepressant
Synthesis
Nortriptyline is 5-(3-methylaminopropyliden)-10,11-dihydrodibenzcycloheptene (7.1.17). Nortriptyline differs from desipramine in the same manner in which amitriptyline differs from imipramine. In nortriptyline, the nitrogen atom in the central part of the tricyclic system of desipramine is replaced by a carbon atom, which is bound to a side chain by a double bond.
Two suggested methods of nortriptyline synthesis are based on the N-demethylation of amitriptyline. The third way utilizes the reaction of methylamine with 5-(3-bromopropyliden)-10,11-dihydro-5H-dibenz[a,d]cycloheptene (7.1.18).
According to the first scheme, demethylation takes place by the reaction of amitriptyline (7.1.4) with methyliodide, which leads to the formation of a quaternary ammonium salt (7.1.16), the reaction of which with methylamine at a relatively high temperature gives the desired nortriptyline (7.1.17) [25].
According to the third scheme, nortriptyline is synthesized by reacting methylamine with 5-(3-bromopropyliden)-10,11-dihydro-5H-dibenz[a,d]cycloheptene (7.1.6) [8].
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
flecainide or propafenone; avoid with dronedarone. Antibacterials: increased risk of ventricular
arrhythmias with delamanid, moxifloxacin and
possibly telithromycin - avoid with moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: enhanced CNS excitation and
hypertension with MAOIs and moclobemide -
avoid; concentration possibly increased with SSRIs;
risk of ventricular arrhythmias with citalopram and
escitalopram - avoid; increased risk of convulsions
with vortioxetine.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
fosphenytoin, phenobarbital and possibly phenytoin.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, haloperidol,
pimozide, risperidone and sulpiride - avoid;
increased antimuscarinic effects with clozapine
and phenothiazines; concentration increased by
antipsychotics.
Antivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.
Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Clonidine: tricyclics antagonise hypotensive effect;
increased risk of hypertension on clonidine withdrawal.
Dapoxetine: possible increased risk of serotonergic
effects - avoid.
Dopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Pentamidine: increased risk of ventricular
arrhythmias.
Sympathomimetics: increased risk of hypertension
and arrhythmias with adrenaline and noradrenaline;
metabolism possibly inhibited by methylphenidate.
Metabolism
Nortriptyline is a secondary amine dibenzocycloheptene TCA as well as the major metabolite of
amitriptyline. Similar to desipramine, nortriptyline appears in mother's milk and is metabolized by CYP2D6 to
the primary amine and by ring hydroxylation to its E-10-hydroxy metabolite. Approximately
one-third of a dose of nortriptyline is excreted in urine as metabolites within 24 hours, and small amounts are
excreted in feces via biliary elimination.
Check Digit Verification of cas no
The CAS Registry Mumber 72-69-5 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 72-69:
(4*7)+(3*2)+(2*6)+(1*9)=55
55 % 10 = 5
So 72-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
72-69-5Relevant articles and documents
NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation
Blaess, Markus,Bibak, Nelly,Claus, Ralf A.,Kohl, Matthias,Bonaterra, Gabriel A.,Kinscherf, Ralf,Laufer, Stefan,Deigner, Hans-Peter
supporting information, p. 73 - 104 (2017/10/17)
Ceramide generation is involved in signal transduction of cellular stress response, in particular during stress-induced apoptosis in response to stimuli such as minimally modified Low-density lipoproteins, TNFalpha and exogenous C6-ceramide. In this paper we describe 48 diverse synthetic products and evaluate their lysosomotropic and acid sphingomyelinase inhibiting activities in macrophages. A stimuli-induced increase of C16-ceramide in macrophages can be almost completely suppressed by representative compound NB 06 providing an effective protection of macrophages against apoptosis. Compounds like NB 06 thus offer highly interesting fields of application besides prevention of apoptosis of macrophages in atherosclerotic plaques in vessel walls. Most importantly, they can be used for blocking pH-dependent lysosomal processes and enzymes in general as well as for analyzing lysosomal dependent cellular signaling. Modulation of gene expression of several prominent inflammatory messengers IL1B, IL6, IL23A, CCL4 and CCL20 further indicate potentially beneficial effects in the field of (systemic) infections involving bacterial endotoxins like LPS or infections with influenza A virus.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
-
, (2015/05/26)
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy.
